Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 25:68:e240422.
doi: 10.20945/2359-4292-2024-0422. eCollection 2024.

Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)

Rodrigo O Moreira  1   2   3 , Cynthia M Valerio  1 , Alexandre Hohl  4 , Cristiane Moulin  5 , Fábio Moura  6   7 , Fábio R Trujilho  8 , Fernando Gerchman  9   10 , Livia L Correa  1 , Marcio C Mancini  11 , Maria Edna Melo  11 , Rodrigo N Lamounier  12   13 , Simone van de Sande-Lee  4 , Thaísa D G Trujilho  8 , Paulo A C Miranda  13   14 , Bruno Halpern  15
Affiliations
Review

Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)

Rodrigo O Moreira et al. Arch Endocrinol Metab. .

Abstract

Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), with the aim of reviewing all the approved medications for the management of obesity in Brazil (sibutramine, orlistat, liraglutide, semaglutide and bupropion/naltrexone fixed dose), with the addition of tirzepatide, that is approved in other countries and likely approved soon in Brazil. The review is focused on efficacy, safety profile and the impact of drugs (based on existing studies) on different comorbidities.

Keywords: Obesity; antiobesity drugs; weight loss.

PubMed Disclaimer

References

    1. World Obesity Federation World Obesity Atlas 2023. [Accessed on: Jun 2024]. https://data.worldobesity.org/publications/?cat=19
    1. Halpern B, Halpern A. Why are anti-obesity drugs stigmatized? Expert Opin Drug Saf. 2015;14(2):185–189. doi: 10.1517/14740338.2015.995088. - DOI - PubMed
    1. Almazan E, Schwartz JL, Gudzune KA. Use of medications associated with weight change among participants in the All of Us research programme. Clin Obes. 2023;13(5):e12609. doi: 10.1111/cob.12609. - DOI - PMC - PubMed
    1. Xia Y, Kelton CM, Guo JJ, Bian B, Heaton PC. Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010. Obesity (Silver Spring) 2015;23(8):1721–1728. doi: 10.1002/oby.21136. - DOI - PubMed
    1. Halpern B, Mancini MC, van de Sande-Lee S, Miranda PAC. "Anti-obesity medications" or "medications to treat obesity" instead of "weight loss drugs" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM) Arch Endocrinol Metab. 2023;67(4):e230174. doi: 10.20945/2359-4292-2023-0174. - DOI - PMC - PubMed

Substances

LinkOut - more resources